Leonard E. Post Sells 1,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Leonard E. Post also recently made the following trade(s):

• On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The stock was sold at an average price of $34.54, for a total transaction of $34,540.00.

CG Oncology Trading Down 2.5 %

CG Oncology stock traded down $0.71 during midday trading on Tuesday, reaching $27.97. 597,149 shares of the company’s stock were exchanged, compared to its average volume of 703,322. The stock’s 50-day simple moving average is $32.28 and its 200 day simple moving average is $34.25. CG Oncology, Inc. has a 52 week low of $25.77 and a 52 week high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. Analysts expect that CG Oncology, Inc. will post -1.32 earnings per share for the current year.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of CG Oncology by 59.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company’s stock valued at $1,172,000 after buying an additional 11,542 shares in the last quarter. Franklin Resources Inc. lifted its stake in CG Oncology by 8.9% during the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company’s stock worth $46,157,000 after purchasing an additional 100,106 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of CG Oncology in the 3rd quarter valued at $1,120,000. Geode Capital Management LLC increased its stake in shares of CG Oncology by 96.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company’s stock valued at $40,701,000 after purchasing an additional 528,749 shares during the last quarter. Finally, M&T Bank Corp raised its holdings in shares of CG Oncology by 55.7% during the 3rd quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock worth $632,000 after buying an additional 5,996 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CGON shares. Bank of America restated a “buy” rating and set a $65.00 price target on shares of CG Oncology in a report on Tuesday, October 8th. UBS Group assumed coverage on CG Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $60.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Friday. Royal Bank of Canada reissued an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research report on Friday, December 6th. Finally, TD Cowen began coverage on shares of CG Oncology in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.